Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171876 | 0.84 | SMN1; SMN2 (0.54) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| SCHEMBL781082 | 0.80 | PIK3CA (0.48) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| SCHEMBL780097 | 0.80 | PIK3CA (0.48) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| SCHEMBL780100 | 0.77 | PIK3CA (0.46) | SMN1; SMN2PIK3CAKMT2AMAPTTSHR | |
| SCHEMBL18171877 | 0.76 | DGAT1 (0.43) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| SCHEMBL782822 | 0.76 | PIK3CA (0.45) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL781422 | 0.76 | PIK3CA (0.45) | SMN1; SMN2PIK3CAKMT2AMAPTTSHR | |
| SCHEMBL21842701 | 0.75 | SMN1; SMN2 (0.44) | MAOBSMN1; SMN2PIK3CAKMT2AMAPT | |
| SCHEMBL6617981 | 0.74 | ROCK2 (0.46) | SMN1; SMN2PIK3CAKMT2AMAPTTSHR | |
| SCHEMBL6619442 | 0.74 | ROCK2 (0.46) | SMN1; SMN2PIK3CAKMT2AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| CN-102459234-A | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD | 2012-05-16 | — | — | CN | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | MAOB 2432/4885SMN1; SMN2 2266/4885PIK3CA 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.